HIV-1 Env fusion peptide immunogens and their use

US11602559B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Rui Kong · Bethesda, US
• Tongqing Zhou · Boyds, US
• John Mascola · Rockville, US
• Kai Xu · Bethesda, US
• Cheng Cheng · Bethesda, US
• Gwo-Yu Chuang · Rockville, US
• Kevin G. Liu · Plainsboro, US
• Baoshan Zhang · Bethesda, US
• Li Ou · Bethesda, US
• Wing-Pui Kong · Germantown, US

Key dates

• Filing date: Oct 3, 2017
• Grant date: Mar 14, 2023
• Expiry date: Oct 16, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.